Compare LXRX & DVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LXRX | DVS |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 446.5M |
| IPO Year | 2000 | N/A |
| Metric | LXRX | DVS |
|---|---|---|
| Price | $1.66 | $2.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.15 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 03-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.33 | $2.48 |
| 52 Week High | $1.83 | $5.93 |
| Indicator | LXRX | DVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 26.02 |
| Support Level | $1.08 | N/A |
| Resistance Level | $1.81 | $5.04 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 50.91 | 10.13 |
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.